Biogen (BIIB) PT Raised to $341 at RBC Capital following neurologist survey on donamenab
Tweet Send to a Friend
(Updated - July 11, 2023 6:41 AM EDT)
RBC Capital analyst Brian Abrahams raised the price target on Biogen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
RBC Capital analyst Brian Abrahams raised the price target on Biogen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
